Treatment of murine lupus with anti-CD4 monoclonal antibodies.
Extensive studies in lupus-prone mice strongly suggest that mAbs to CD4 may be effective in SLE. By virtue of their selectivity for distinct cells within the immune system, anti-CD4 mAbs may be both more potent and less toxic than current therapies for SLE. In addition, their potential to block the host immune response to therapy may provide a critical advantage for anti-CD4 compared to other forms of mAb therapy. The problem of generalized immune suppression remains a significant obstacle to the use of anti-CD4 in humans, but it may be minimized by the use of mAb fragments or mAb isotypes that can reversibly inhibit immune function without depleting CD4+ T cells.
Wofsy
D
D
University of California-San Francisco.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D001323:Autoantibodies / Q000096:biosynthesis; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D004195:Disease Models, Animal; D007109:Immunity; D007128:Immunoglobulin Fragments / Q000627:therapeutic use; D007167:Immunotherapy; D008180:Lupus Erythematosus, Systemic / Q000628:therapy*; D051379:Mice; D008814:Mice, Inbred NZB
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D007128:Immunoglobulin Fragments